2024
A virus associated with the zoonotic pathogen Plasmodium knowlesi causing human malaria is a member of a diverse and unclassified viral taxon
Petrone M, Charon J, Grigg M, William T, Rajahram G, Westaway J, Piera K, Shi M, Anstey N, Holmes E. A virus associated with the zoonotic pathogen Plasmodium knowlesi causing human malaria is a member of a diverse and unclassified viral taxon. Virus Evolution 2024, veae091. DOI: 10.1093/ve/veae091.Peer-Reviewed Original ResearchViral taxaRNA virusesAnalysis of metagenomic dataPlasmodium speciesSingle-celled eukaryotesHuman-infecting Plasmodium speciesPathogen life cycleGenome architectureGroup of virusesMetagenomic dataMetagenomic sequencingDisease-causingVirus discoveryTaxaViral diversityParasite PlasmodiumRNAInfecting protozoaPlasmodium knowlesiViromeHuman malariaParasite fitnessSpeciesApicomplexaInfect humansNo evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
Parry R, Lytras S, Petrone M, Wille M, Crits-Christoph A, Gifford R, Saito A, Smura T, Peacock T. No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota. Journal Of Virology 2024, e0146824. PMID: 39494907, DOI: 10.1128/jvi.01468-24.Peer-Reviewed Original ResearchBacterial sequencesViral RNA-dependent RNA polymeraseRNA-dependent RNA polymeraseSARS-CoV-2 variantsBacterial protein sequencesSARS-CoV-2 proteinsEvolution of mutationsRNA polymeraseIntrahost diversityProtein sequencesHomologous fragmentsNucleotide sequenceProtein databaseTemplate-switchingGut microbiotaSARS-CoV-2 VOCsViral genomeSARS-CoV-2Mutated fragmentsAmino acidsRdRpMutationsSequenceViral replicationProteinA ~40-kb flavi-like virus does not encode a known error-correcting mechanism
Petrone M, Grove J, Mélade J, Mifsud J, Parry R, Marzinelli E, Holmes E. A ~40-kb flavi-like virus does not encode a known error-correcting mechanism. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2403805121. PMID: 39018195, PMCID: PMC11287256, DOI: 10.1073/pnas.2403805121.Peer-Reviewed Original ResearchConceptsFlavi-like virusGenome sizeRNA virusesRNA virus genomesNucleic acid metabolismGenome lengthPhylogenetic inferenceDeleterious mutationsExonuclease domainGenomeVirus genomeProofreading mechanismPopulation extinctionMutation rateRNAAcid metabolismExonucleaseMutationsVirusMetatranscriptomicsStructural analysisLineagesProofreadingMechanismMetabolismDengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virus
Vogels C, Hill V, Breban M, Chaguza C, Paul L, Sodeinde A, Taylor-Salmon E, Ott I, Petrone M, Dijk D, Jonges M, Welkers M, Locksmith T, Dong Y, Tarigopula N, Tekin O, Schmedes S, Bunch S, Cano N, Jaber R, Panzera C, Stryker I, Vergara J, Zimler R, Kopp E, Heberlein L, Herzog K, Fauver J, Morrison A, Michael S, Grubaugh N. DengueSeq: a pan-serotype whole genome amplicon sequencing protocol for dengue virus. BMC Genomics 2024, 25: 433. PMID: 38693476, PMCID: PMC11062901, DOI: 10.1186/s12864-024-10350-x.Peer-Reviewed Original ResearchConceptsAmplicon sequencing protocolsPrimer schemeSequencing protocolGenomic surveillanceDengue virus serotypesAmplicon sequencing workflowClinical specimensHigh genome coverageWhole-genome sequencingDengue virusVirus serotypesGenome coverageVirus stocksGenetic diversitySequencing instrumentsSequencing workflowGenotype VIDiverse serotypesSequence of samplesGenotype IVPrimersSurveillance of dengue virusSerotypesVirus copiesSerotype-specific
2023
Evidence for an ancient aquatic origin of the RNA viral order Articulavirales
Petrone M, Parry R, Mifsud J, Van Brussel K, Voorhees I, Richards Z, Holmes E. Evidence for an ancient aquatic origin of the RNA viral order Articulavirales. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2310529120. PMID: 37906647, PMCID: PMC10636315, DOI: 10.1073/pnas.2310529120.Peer-Reviewed Original ResearchConceptsEvolutionary historyAquatic-terrestrial transitionsDeep phylogenetic historiesVirus-host codivergenceMajor evolutionary transitionsLong-term evolutionary processesTotal RNA sequencingClose phylogenetic relationshipTranscriptome data miningPhylogenetic diversityEvolutionary transitionsPhylogenetic historyPhylogenetic relationshipsInfluenza virus lineagesPhylum CnidariaDivergent familiesPutative familiesRNA sequencingAquatic animalsEvolutionary processesNew hostAquatic originDisease-causing virusesEmergence of virusesVirus lineages
2022
Evaluation of saliva self-collection devices for SARS-CoV-2 diagnostics
Allicock OM, Petrone ME, Yolda-Carr D, Breban M, Walsh H, Watkins AE, Rothman JE, Farhadian SF, Grubaugh ND, Wyllie AL. Evaluation of saliva self-collection devices for SARS-CoV-2 diagnostics. BMC Infectious Diseases 2022, 22: 284. PMID: 35337266, PMCID: PMC8953967, DOI: 10.1186/s12879-022-07285-7.Peer-Reviewed Original ResearchComparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA
Earnest R, Uddin R, Matluk N, Renzette N, Turbett SE, Siddle KJ, Loreth C, Adams G, Tomkins-Tinch CH, Petrone ME, Rothman JE, Breban MI, Koch RT, Billig K, Fauver JR, Vogels CBF, Bilguvar K, De Kumar B, Landry ML, Peaper DR, Kelly K, Omerza G, Grieser H, Meak S, Martha J, Dewey HB, Kales S, Berenzy D, Carpenter-Azevedo K, King E, Huard RC, Novitsky V, Howison M, Darpolor J, Manne A, Kantor R, Smole SC, Brown CM, Fink T, Lang AS, Gallagher GR, Pitzer VE, Sabeti PC, Gabriel S, MacInnis BL, Team N, Altajar A, DeJesus A, Brito A, Watkins A, Muyombwe A, Blumenstiel B, Neal C, Kalinich C, Liu C, Loreth C, Castaldi C, Pearson C, Bernard C, Nolet C, Ferguson D, Buzby E, Laszlo E, Reagan F, Vicente G, Rooke H, Munger H, Johnson H, Tikhonova I, Ott I, Razeq J, Meldrim J, Brown J, Wang J, Vostok J, Beauchamp J, Grimsby J, Hall J, Messer K, Larkin K, Vernest K, Madoff L, Green L, Webber L, Gagne L, Ulcena M, Ray M, Fisher M, Barter M, Lee M, DeFelice M, Cipicchio M, Smith N, Lennon N, Fitzgerald N, Kerantzas N, Hui P, Harrington R, Downing R, Haye R, Lynch R, Anderson S, Hennigan S, English S, Cofsky S, Clancy S, Mane S, Ash S, Baez S, Fleming S, Murphy S, Chaluvadi S, Alpert T, Rivard T, Schulz W, Mandese Z, Tewhey R, Adams M, Park D, Lemieux J, Grubaugh N. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Reports Medicine 2022, 3: 100583. PMID: 35480627, PMCID: PMC8913280, DOI: 10.1016/j.xcrm.2022.100583.Peer-Reviewed Original ResearchConceptsEnhanced transmissibilitySARS-CoV-2 variant DeltaSARS-CoV-2 Delta variantViral RNA copiesPublic health programsAlpha infectionDelta infectionEffective reproductive numberDelta variantHealth programsVariant DeltaRNA copiesInfectionAlphaReproductive numberTransmissibilityEpidemiological dynamicsSequencing SARS-CoV-2 genomes from saliva
Alpert T, Vogels CBF, Breban MI, Petrone ME, Wyllie A, Grubaugh N, Fauver J. Sequencing SARS-CoV-2 genomes from saliva. Virus Evolution 2022, 8: veab098. PMID: 35542310, PMCID: PMC9074962, DOI: 10.1093/ve/veab098.Peer-Reviewed Original Research
2021
A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice
Mao T, Israelow B, Lucas C, Vogels CBF, Gomez-Calvo ML, Fedorova O, Breban MI, Menasche BL, Dong H, Linehan M, Alpert T, Anderson F, Earnest R, Fauver J, Kalinich C, Munyenyembe K, Ott I, Petrone M, Rothman J, Watkins A, Wilen C, Landry M, Grubaugh N, Pyle A, Iwasaki A. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal Of Experimental Medicine 2021, 219: e20211818. PMID: 34757384, PMCID: PMC8590200, DOI: 10.1084/jem.20211818.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionChronic SARS-CoV-2 infectionVariants of concernLethal SARS-CoV-2 infectionPost-infection therapyLower respiratory tractPost-exposure treatmentType I interferonSARS-CoV-2Effective medical countermeasuresAdaptive immune systemBroad-spectrum antiviralsContext of infectionSingle doseRespiratory tractViral controlImmunodeficient miceSevere diseaseMouse modelI interferonViral infectionImmune systemInnate immunityDisease preventionConsiderable efficacyDiverse functional autoantibodies in patients with COVID-19
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Dela Cruz C, Farhadian S, Schulz W, Ma S, Grubaugh N, Ko A, Iwasaki A, Ring A. Diverse functional autoantibodies in patients with COVID-19. Nature 2021, 595: 283-288. PMID: 34010947, DOI: 10.1038/s41586-021-03631-y.Peer-Reviewed Original ResearchConceptsPeripheral immune cell compositionSARS-CoV-2 infectionCOVID-19Effects of autoantibodiesTissue-associated antigensSpecific clinical characteristicsInnate immune activationImmune cell compositionCOVID-19 exhibitCOVID-19 manifestsAnalysis of autoantibodiesSARS-CoV-2Functional autoantibodiesMouse surrogateClinical characteristicsVirological controlClinical outcomesImmune activationMild diseaseAsymptomatic infectionAutoantibody reactivityDisease progressionHealthcare workersHigh prevalenceAutoantibodiesEarly introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States
Alpert T, Brito AF, Lasek-Nesselquist E, Rothman J, Valesano AL, MacKay MJ, Petrone ME, Breban MI, Watkins AE, Vogels CBF, Kalinich CC, Dellicour S, Russell A, Kelly JP, Shudt M, Plitnick J, Schneider E, Fitzsimmons WJ, Khullar G, Metti J, Dudley JT, Nash M, Beaubier N, Wang J, Liu C, Hui P, Muyombwe A, Downing R, Razeq J, Bart SM, Grills A, Morrison SM, Murphy S, Neal C, Laszlo E, Rennert H, Cushing M, Westblade L, Velu P, Craney A, Cong L, Peaper DR, Landry ML, Cook PW, Fauver JR, Mason CE, Lauring AS, St George K, MacCannell DR, Grubaugh ND. Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. Cell 2021, 184: 2595-2604.e13. PMID: 33891875, PMCID: PMC8018830, DOI: 10.1016/j.cell.2021.03.061.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 lineage B.1.1.7SARS-CoV-2 variant B.1.1.7Global public health concernPublic health concernPublic health responseCOVID-19 casesLineage B.1.1.7Variant B.1.1.7Health responseHealth concernB.1.1.7Increased transmissibilityEarly introductionGenomic surveillanceUnited StatesDiagnostic dataDominant lineageAsynchronicity of endemic and emerging mosquito-borne disease outbreaks in the Dominican Republic
Petrone ME, Earnest R, Lourenço J, Kraemer MUG, Paulino-Ramirez R, Grubaugh ND, Tapia L. Asynchronicity of endemic and emerging mosquito-borne disease outbreaks in the Dominican Republic. Nature Communications 2021, 12: 151. PMID: 33420058, PMCID: PMC7794562, DOI: 10.1038/s41467-020-20391-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAedesAnimalsChikungunya FeverChikungunya virusChildChild, PreschoolCommunicable Diseases, EmergingDengueDengue VirusDisease OutbreaksDominican RepublicEndemic DiseasesEpidemiological MonitoringFemaleHumansInfantInfant, NewbornMaleMosquito ControlMosquito VectorsSpatio-Temporal AnalysisYoung AdultZika VirusZika Virus InfectionConceptsDengue outbreakDisease outbreaksDengue fever casesOutbreak of chikungunyaMosquito-Borne VirusesFever casesFuture health crisesMosquito-borne disease outbreaksFuture outbreaksVirus transmissionAedes mosquitoesSustainable disease control measuresHealth crisisVirusDisease control measuresOutbreakChikungunyaConstant surveillanceZikaControl measuresDominican Republic
2020
Virus genomics as a clinical and epidemiological tool
Petrone M. Virus genomics as a clinical and epidemiological tool. EBioMedicine 2020, 62: 103141. PMID: 33249382, PMCID: PMC7691135, DOI: 10.1016/j.ebiom.2020.103141.Peer-Reviewed Original ResearchSaliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2
Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. New England Journal Of Medicine 2020, 383: 1283-1286. PMID: 32857487, PMCID: PMC7484747, DOI: 10.1056/nejmc2016359.Peer-Reviewed Original ResearchCoast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States
Fauver JR, Petrone ME, Hodcroft EB, Shioda K, Ehrlich HY, Watts AG, Vogels CBF, Brito AF, Alpert T, Muyombwe A, Razeq J, Downing R, Cheemarla NR, Wyllie AL, Kalinich CC, Ott IM, Quick J, Loman NJ, Neugebauer KM, Greninger AL, Jerome KR, Roychoudhury P, Xie H, Shrestha L, Huang ML, Pitzer VE, Iwasaki A, Omer SB, Khan K, Bogoch II, Martinello RA, Foxman EF, Landry ML, Neher RA, Ko AI, Grubaugh ND. Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. Cell 2020, 181: 990-996.e5. PMID: 32386545, PMCID: PMC7204677, DOI: 10.1016/j.cell.2020.04.021.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Federal travel restrictionsSARS-CoV-2 transmissionCOVID-19 patientsCoronavirus SARS-CoV-2SARS-CoV-2 introductionsEarly SARS-CoV-2 transmissionPattern of spreadSustained transmissionLocal surveillanceEarly epidemicInternational importationCOVID-19 outbreakUnited StatesViral genomeInternational travel patternsPatientsCritical needTravel restrictions
2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal Of Medicine 2016, 375: 2037-2050. PMID: 27959728, PMCID: PMC5292134, DOI: 10.1056/nejmoa1608243.Peer-Reviewed Original ResearchConceptsPlasma viral reboundHuman immunodeficiency virusAntiretroviral therapyViral reboundViral suppressionHIV infectionPassive immunizationHistorical controlsWeek 8Interruption of ARTNeutralization-resistant virusesOpen-label trialSide effect profileART interruptionSingle bNAbsTreatment interruptionAdverse eventsMedian timeImmunodeficiency virusNIH trialPassive administrationHIV CD4Week 4Antibody VRC01Trial participants